Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 10/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | EED | O75530 | 2/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868398 | 0.79 | MTNR1A (0.49) | MTNR1ATGM2KDM4CHTR2AHTR2C | |
| SCHEMBL1011204 | 0.78 | MTNR1A (0.82) | MTNR1AKDM4CMTNR1B | |
| SCHEMBL22353062 | 0.76 | MTNR1A (0.38) | MTNR1ATGM2KDM4CHTR2AHTR2C | |
| SCHEMBL14868406 | 0.74 | MTNR1A (0.47) | MTNR1ATGM2KDM4CHTR2AHTR2C | |
| SCHEMBL14868378 | 0.73 | MTNR1A (0.49) | MTNR1ATGM2KDM4CHTR2AHTR2C | |
| SCHEMBL17186442 | 0.73 | MTNR1A (0.54) | MTNR1ATGM2KDM4CHTR2AHTR2C | |
| SCHEMBL14868393 | 0.73 | MTNR1A (0.51) | MTNR1ATGM2KDM4CHTR2AHTR2C | |
| SCHEMBL14868414 | 0.71 | MTNR1A (0.49) | MTNR1ATGM2KDM4CHTR2AHTR2C | |
| SCHEMBL17186299 | 0.70 | MTNR1A (0.51) | MTNR1AHTR2AHTR2C | |
| SCHEMBL11044001 | 0.70 | EED (0.44) | MTNR1AKDM4CHTR2AHTR2CEED |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2800561-B1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMA US LLC (US) | 2020-08-19 | — | — | EP | disclosed |